Biosimilar Monoclonal Antibody Market
According to Intent Market Research, the Biosimilar Monoclonal Antibody Market is expected to grow from USD 374.6 billion in 2023 at a CAGR of 9.1% to touch USD 689.6 billion by 2030. The Biosimilar Monoclonal Antibody Market is dominated by key players such as Amgen, BIOCAD, Biocon, Biogen, Novartis, Pfizer, Shanghai Henlius Biotech, and Teva Pharmaceutical.